Novartis gets FDA nod for blood-pressure pill

Share this article:
The FDA approved Novartis’ Exforge, a hypertension drug combining two currently marketed cardiovascular medicines. Novartis called the approval “tentative,” as it won’t launch Exforge until late September 2007 pending the expiration of market exclusivity and patent protection for Pfizer’s Norvasc (amlodipine besylate). The new pill brings together Norvasc, a calcium channel blocker, with Novartis’ Diovan (valsartan), an angiotensin II antagonist. Analysts say the most obvious market for Exforge are the over $4.5 billion of global sales Pfizer makes with Norvasc, but the pill also may help to prolong the life cycle for Diovan. Both Norvasc and Diovan are the top-selling therapies in their respective categories. Norvasc had US sales of $2.6 billion in 2005, while Diovan racked up 2005 sales of $1.04 billion, according to IMS Health. In November, Exforge received a positive opinion by the Committee for Medicinal Products for Human Use (CHMP)—the regulatory agency that reviews European Union submissions for new medicines—Novartis said, adding it expects approval from the European Commission and launch in the EU during the first half of 2007. Novartis has another hypertension drug under review, the renin inhibitor Tekturna (aliskiren). A spokesman said the firm expects a US regulatory decision in the first half of 2007.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...